Previous 10 |
home / stock / cltef / cltef news
Calliditas Therapeutics AB (CALT) Q1 2021 Earnings Conference Call May 18, 2021 08:30 AM ET Company Participants Renée Lucander - CEO Richard Philipson - Chief Medical Officer Fredrik Johansson - CFO Andrew Udell - President, North America Conference Call Participants Yigal Nochomovitz -...
The following slide deck was published by Calliditas Therapeutics AB (publ) in conjunction with their 2021 Q1 earnings call. For further details see: Calliditas Therapeutics AB (publ) 2021 Q1 - Results - Earnings Call Presentation
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...
Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM , April 26, 2021 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm , are summoned to t...
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy PR Newswire STOCKHOLM , April 23, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its lead p...
Calliditas strengthens its US Commercial and Medical Affairs Organization PR Newswire STOCKHOLM , March 8, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced the appointment of three industry veterans: Warren Brooks , PhD,...
Positive Phase 1 results in high-dose setanaxib trial PR Newswire STOCKHOLM , Jan. 18, 2021 /PRNewswire/ -- Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT), today announced positive Phase 1 data...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB - Class B Company Name:
CLTEF Stock Symbol:
OTCMKTS Market:
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics' 2020 Annual Report Published PR Newswire STOCKHOLM , April 27, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2020 now is available at the company's...